Expression data from in vivo experiment comparing untreated controls with animals treated with bevacizumab (Avastin)

ABSTRACT: Bevacizumab induces glioblastoma resistance in two in vivo xenograft models. Two cell lines were developed with acquired resistance to bevacizumab. Gene expression difference were analyzed between treated and untreated tumors. Purpose: Antiangiogenic therapy reduces vascular permeability and delays progression but may ultimately promote an aggressive treatment-resistant phenotype. The aim of the present study was to identify mechanisms responsible for glioblastoma resistance to antiangiogenic therapy. Experimental Design: Glioma stem cell (GSC) NSC11 and U87 cell lines with acquired resistance to bevacizumab were developed from orthotopic xenografts in nude mice treated with bevacizumab. Genome-wide analyses were used to identify changes in tumor subtype and specific factors associated w

ORGANISM(S): Homo sapiens

SUBMITTER: Piao Y 

PROVIDER: S-ECPF-GEOD-45161 | biostudies-other | 2013 Aug

REPOSITORIES: biostudies-other